JBC Associates logo
BioProspect AI

AI-Powered Lead Prospecting for Life Science Sales Teams

Find Your Target Companies and Reach the Right Prospects

BioProspect AI™ rapidly identifies target companies and decision-makers for life science tools, laboratory equipment, CRO, CDMO, and biotech sales teams. It combines company characterization, market intelligence, prospect data, and personalized AI multichannel messaging in one workflow.

See a Demo
BioProspect Company Intelligence
AI COMPANY CHARACTERIZATION
TxDxCDMO/CROPlatformGeneric/Biosimilar
VE
VerimmuneTherapeutics company
94% FIT
Therapeutics (Tx)
Yes
Synthetic proteins
Multiple myeloma · AML
Preclinical, Phase I
Commercial match Strong fit for providers supporting synthetic protein discovery, screening, biomarker, and analytical workflows.
AR
ArcadiaTherapeutics company
89% FIT
Therapeutics (Tx)
No
Small molecules
Oncology · CNS · Rare disease
Preclinical, Phase I
Commercial match Strong fit for CRO, CDMO, chemistry, screening, and analytical partners serving small-molecule development teams.
1000Xfaster than manual prospect research and delivery
One Viewcompanies, prospects, context, and outreach together
High-Fitprioritizes accounts and contacts aligned with the ICP
Natural soundingAI messages using company and prospect information

All Your Tools in a Simple Worklfow

Traditional Prospecting

Salespeople repeatedly search, copy, switch tools, and retrace steps to research companies, identify prospects, manage activity, and handle outreach.

CRM Message your contact
Crunchbase Locate and research companies
Professional Network Identify prospect info and contact data
Other Tools WhatsApp and SMS

BioProspect AI

One push-button workflow brings company research, prospect identification, contact data, and tailored outreach together—making the process simple to scale.

Prospect Intelligence▶ PUSH TO SCALE
Dr. Maya Chen VP, Synthetic Protein Discovery
Emailmchen@verimmune.com
Phone(617) 555-0139
CompanyVerimmune
Job DescriptionLeads synthetic protein discovery strategy and evaluates enabling technologies for screening, biomarker analysis, and program progression.
Your team’s synthetic protein programs in multiple myeloma and AML suggest that higher-quality screening and sensitive biomarker workflows may be increasingly important as Verimmune progresses from preclinical work toward Phase I activities...

Experienced Life Science Commercial Leadership

Built on 100+ years in life science tools and laboratory equipment, and CRO and CDMO services

Finally, a Prospecting Tool for the Life Science Sales Rep!

Contact us for a demo or evaluation.

Schedule a Demo Request an Evaluation